Ligustrazine hydrochloride

Synonyms: 盐酸川芎嗪; Chuanxiongzine hydrochloride; Tetramethylpyrazine hydrochloride
Ligustrazine hydrochloride 是一种具有口服活性、可穿透血脑屏障的生物碱,可从 Ligusticum striatum DC 中分离得到,能减少 ROS,上调 p-Akt/Akt 与 p-eNOS/eNOS 的水平,减少 ALT 和 AST,抑制谷氨酸兴奋性毒性、钙超载、氧化应激、缺血再灌注损伤及动脉粥样硬化斑块进展,增强突触可塑性,并改善神经功能、脑梗死体积及脑含水量,具备抗炎、抗氧化、降脂、内皮保护、保肝活性,可用于缺血性脑卒中、脑缺血再灌注损伤及动脉粥样硬化的相关研究。
产品编号: MS-V38595 纯度: 99.93% CAS No.: 76494-51-4 分子式: C8H12N2.xHCl
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
3-5 天
100mg
询价
3-5 天
250mg
询价
3-5 天
500mg
询价
3-5 天
1g
询价
3-5 天
5g
询价
3-5 天
10g
询价
3-5 天
50g
询价
询价

产品描述

Ligustrazine hydrochloride 是一种具有口服活性、可穿透血脑屏障的生物碱,可从 Ligusticum striatum DC 中分离得到,能减少 ROS,上调 p-Akt/Akt 与 p-eNOS/eNOS 的水平,减少 ALT 和 AST,抑制谷氨酸兴奋性毒性、钙超载、氧化应激、缺血再灌注损伤及动脉粥样硬化斑块进展,增强突触可塑性,并改善神经功能、脑梗死体积及脑含水量,具备抗炎、抗氧化、降脂、内皮保护、保肝活性,可用于缺血性脑卒中、脑缺血再灌注损伤及动脉粥样硬化的相关研究。

生物实验数据

生物活性 Ligustrazine hydrochloride is an orally active alkaloid capable of penetrating the blood-brain barrier that can be isolated from Ligusticum striatum DC; it reduces ROS, upregulates p-Akt/Akt and p-eNOS/eNOS levels, decreases ALT and AST, inhibits glutamate excitotoxicity, calcium overload, oxidative stress, ischemia-reperfusion injury, and atherosclerotic plaque progression, enhances synaptic plasticity, and improves neurological function, cerebral infarct volume, and brain water content, possessing anti-inflammatory, antioxidant, lipid-lowering, endothelial-protective, and hepatoprotective activities, and can be used in studies related to ischemic stroke, cerebral ischemia-reperfusion injury, and atherosclerosis.
IC50 & Target

eNOS

 

体外研究
(In Vitro)

Ligustrazine (1-100 μM) hydrochloride 可通过激活 PI3K/Akt 通路,呈剂量依赖性地增加 OGD 处理的羊膜上皮细胞中 NO 的生成,但对正常 HAECs 的 NO 生成无显著影响。
Ligustrazine (0.1-10 μM) hydrochloride 可通过激活 PI3K/Akt 通路,以剂量依赖方式上调氧糖剥夺 (OGD) 处理的羊膜上皮细胞中 p-Akt/Akt 与 p-eNOS/eNOS 的水平,而对正常 HAECs 中的上述因子无显著影响。
Ligustrazine hydrochloride 可在体外细胞模型中保护内皮细胞免受 LDL 诱导的损伤。

体内研究
(In Vivo)

Ligustrazine (10-120 mg/kg;腹腔注射;静脉注射;口服) hydrochloride 对缺血性中风大鼠模型具有保护作用,可显著改善神经功能、降低脑损伤标志物水平、调控炎症和氧化应激通路、抑制细胞凋亡并修复血脑屏障通透性。
Ligustrazine (20 mg/kg;腹腔注射;造模后 15 min) hydrochloride 可改善雄性 C57BL/6 小鼠缺血性卒中模型的神经功能。
Ligustrazine (1-10 mg/kg;腹腔注射;术后 2 小时和 12 小时各给予 1 次) hydrochloride 可通过激活 PI3K/Akt 通路,以剂量依赖性方式保护 Wistar 大鼠免受脑缺血再灌注损伤;该通路可提升 p-Akt 和 p-eNOS 水平、改善神经功能并减轻脑组织损伤。
Ligustrazine (20-80 mg/kg;口服;6 周) hydrochloride 可剂量依赖性地抑制 Sprague-Dawley 大鼠的动脉粥样硬化进展及肝脏脂质蓄积,其中每日口服 80 mg/kg 的剂量可使主动脉病变面积较未治疗的动脉粥样硬化对照组减少 49.0%。

Animal Model: Wistar rats
Dosage: 1 mg/kg; 3 mg/kg; 10 mg/kg
Administration: i.p.; twice (at 2 hours and 12 hours after operation)
Result: Increased brain tissue levels of p-Akt (normalized to Akt) in a dose-dependent manner.
Increased brain tissue levels of p-eNOS (normalized to eNOS) in a dose-dependent manner.
Significantly improved neurological deficits compared to I/R-only rats.
Dose-dependently alleviated brain cell shrinkage, nuclear deep staining, edema, and necrosis induced by I/R injury.
Had its protective effects reversed by pre-treatment with the PI3K inhibitor wortmannin.
Animal Model: Sprague-Dawley (male, SPF grade, ~200 g at study start, induced via vitamin D3 injection and atherogenic diet)
Dosage: 20 mg/kg; 80 mg/kg
Administration: p.o.; daily; 6 weeks
Result: Decreased total cholesterol by 65.2%, triglycerides by 53.2%, LDL by 71.2%, and slightly increased HDL at 20 mg/kg dose.
Decreased total cholesterol by 76.7%, triglycerides by 77.9%, LDL by 79.0%, and slightly increased HDL at 80 mg/kg dose.
Decreased circulating endothelial cells by 42.2% at 20 mg/kg dose.
Decreased circulating endothelial cells by 60.0% at 80 mg/kg dose.
Decreased ALT by 13.0% and AST by 10.7% at 20 mg/kg dose.
Decreased ALT by 49.7% and AST by 14.3% at 80 mg/kg dose.
Restored total antioxidant capacity and SOD1 activity at both doses.
Decreased MDA generation by 12.8% at 20 mg/kg dose.
Decreased MDA generation by 23.8% at 80 mg/kg dose.
Reduced thoracic aorta lesion area by 18.9% relative to atherosclerotic controls at 20 mg/kg dose.
Reduced thoracic aorta lesion area by 49.0% relative to atherosclerotic controls at 80 mg/kg dose.
Reduced hepatic lipid accumulation, reversed elevated hepatic TG and LDL levels, and restored reduced hepatic HDL levels at both doses.
Dose-dependently inhibited the induction of antioxidant genes (pgc-1α, sod1, catalase, gpx-1) in the aorta and liver, and suppressed mRNA expression of hepatic fatty acid oxidation genes (pgc-1α, pparα, cpt1a) at both doses.
性状 固体
颜色 White to off-white

化学信息

分子式 C8H12N2.xHCl
CAS No. 76494-51-4
别名 盐酸川芎嗪; Chuanxiongzine hydrochloride; Tetramethylpyrazine hydrochloride

储存&溶解度

溶解度信息
DMSO: 50.00 mg/mL, Sonication is recommended.
体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2.00 mg/mL, Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础